Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: hasbeen101 who wrote (3555)	11/3/1998 8:58:00 PM
From: Bill Wexler	Read Replies (2) \| Respond to of 4634

Nonsense. The last presentation to the AUA demonstrated the exact opposite. Phentolamine does not treat ED in any way, shape or form. Period. I can lay out the sequence of events for you: 1) Stock promoters will continue to disseminate misleading information about Vasomax until the very last minute (i.e. right before FDA rejection). 2) The stock will float and bounce around until that day. 3) On the day Vasomax is rejected, the stock will drop quickly into the single digits. 4) Zonagen's managment will immediately issue a press release to the effect that additional clinical trials will be conducted and they will refile. 5) Stock promoters will leak additional rumors about other "products" in the pipeline. 6) The stock will take a small bounce. Print this post out and pin it to your bulletin board, because I guarantee you the above scenario - or something close to it - will take place. I shorted another Woodlands biotech fraud - TXB (TXB management, investors, and promoters have close ties to Zonagen. Baylor College of Medicine has also been involved in both of these frauds), and it followed the same exact pattern.